WITH REJUVE, YOU WILL IMPROVE
DEAD

Serial Number

98644838

Owner

Rejuve Therapeutics, Inc.

Filing Date

Jul 11, 2024

Add to watchlist:

No watchlists yet
View on USPTO

WITH REJUVE, YOU WILL IMPROVE Trademark

Serial Number: 98644838

WITH REJUVE, YOU WILL IMPROVE is a trademark filed by Rejuve Therapeutics, Inc. on July 11, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Rejuve Therapeutics, Inc. (5 trademarks)

1801 Main St STE 1300
Houston, TX 77002-8121

Entity Type: 03

Trademark Details

Filing Date

July 11, 2024

Registration Date

Not Registered

Published for Opposition

July 8, 2025

Goods & Services

Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical preparations for the treatment of COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical preparations for preventing, diagnosing, treating and managing cancer, fibrotic diseases, NASH, Crohn's Disease, osteoarthritis, viral infections, and hepatitis C; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Inhalers for medical purposes, sold filled with pharmaceutical preparations for treating COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical preparations for treating asthma

Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 6, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 6, 2026 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 2, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jul 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 4, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 2, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 2, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 2, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 2, 2025 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 3, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 3, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 3, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 3, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 2, 2025 NWOS
NEW APPLICATION ENTERED
Jul 12, 2024 NWAP